Viridos, Inc.

Synthetic Genomics, Inc.

Pacira Pharmaceuticals, Inc.

William F Lambert

Eric R Moellering

Saheed Imam

Luke Peach

Louie Daniel Garcia

John Verruto

Imad Ajjawi

Liangjin Zhu

Kathleen Kwok

Roberto Spreafico

Randor R Radakovits

Sarah Potts

Fedor I Kuzminov

Jessica N Weir

Lois Gibson

Benjamin W Li

Jessica Greiner

Benjamin Li

The invention provides recombinant algal organisms that have a genetic modification to a gene or nucleic acid sequence encoding an RNA binding domain. In some embodiments the genetic modification can be a functional deletion or attenuation of the gene. The genetic modification results in a mutant organism with increased lipid productivity and/or higher biomass productivity. The lipid products of these mutants can be utilized as biofuels or to manufacture other specialty products. The recombinant mutants can also, optionally, have a genetic modification to a gene encoding an SGI1 polypeptide. Methods of making and using the recombinant algal mutants and methods of producing lipids are also disclosed.

Recombinant algae having high lipid productivity

The invention provides recombinant algal mutants that have a genetic modification to a gene or nucleic acid sequence encoding a WD40 repeat containing protein or domain. The genetic modification of one or more nucleic acid sequences encoding a WD40 repeat containing protein or domain results in a mutant organism with increased lipid productivity and/or higher biomass productivity (as measured by total organic carbon). The genetic modification can be a gene attenuation or functional deletion. The lipid products of these mutants can be utilized as biofuels or for other specialty chemical products. Methods of making and using the recombinant algal mutants and methods of producing lipids are also disclosed.

Mutant photosynthetic organisms having reduced chlorophyll and increased photosynthetic efficiency are provided. The mutant strains have mutated or attenuated: chloroplastic SRP54 gene and SGI1 gene; chloroplastic SRP54 gene and SGI2 gene; chloroplastic SRP54 gene, SGI1, and SGI2 genes are disclosed. The mutant photosynthetic organisms exhibit increased productivity with respect to wild-type strains. Also provided are mutant photosynthetic organisms having mutated or attenuated cytosolic SRP54 genes. Provided herein are methods of producing biomass and other products such as lipids using strains having mutations in an SRP54 gene, SGI1, SGI2 genes, a combination of SGI1/SRP54, and a combination of SGI2 and SRP54 genes. Also included are constructs and methods for attenuating or disrupting SRP54, SGI1, and SGI2 genes.

Genetic modulation of photosynthetic organisms for improved growth

Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a Cof MTX between 5% and 50% of the Cof an immediate release dosage form of MTX, the duration of which lasts from about 1 to about 30 days. Also disclosed are methods of treating autoimmune diseases and cancer by administering these formulations of MTX.

Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent

Growing community of inventors

San Diego, CA, United States of America

William F Lambert